{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:08:17Z","timestamp":1790878097160,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010891","name":"Portola Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ahj.2019.09.017","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T20:32:44Z","timestamp":1571776364000},"page":"145-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation"],"prefix":"10.1016","volume":"220","author":[{"given":"Sean D.","family":"Pokorney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaJuanicia N.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Shrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Kowey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald V.","family":"Naccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Washam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Reiffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.09.017_bb0005","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2004 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.017_bb0010","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Wyse","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.017_bb0015","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.017_bb0020","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa0708789","article-title":"Rhythm control versus rate control for atrial fibrillation and heart failure","volume":"358","author":"Roy","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.017_bb0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1540-8159.2012.03513.x","article-title":"Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis","volume":"36","author":"Chatterjee","year":"2013","journal-title":"PACE"},{"key":"10.1016\/j.ahj.2019.09.017_bb0030","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","article-title":"Amiodarone versus sotalol for atrial fibrillation","volume":"352","author":"Singh","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.017_bb0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2003.08.037","article-title":"Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study","volume":"43","author":"Hagens","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.017_bb0040","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(00)03230-X","article-title":"Rhythm or rate control in atrial fibrillation\u2014Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial","volume":"356","author":"Hohnloser","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.017_bb0045","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/HCQ.0000000000000011","volume":"7","author":"Ha","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2019.09.017_bb0050","unstructured":"Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47."},{"key":"10.1016\/j.ahj.2019.09.017_bb0055","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM200003303421302","article-title":"Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators","volume":"342","author":"Roy","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.017_bb0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0735-1097(03)00559-X","article-title":"Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug","volume":"42","author":"Investigators","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.017_bb0065","first-page":"1741","article-title":"Practical guidelines for clinicians who treat patients with amiodarone","volume":"160","author":"Goldschlager","year":"2000","journal-title":"Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Internal Med"},{"key":"10.1016\/j.ahj.2019.09.017_bb0070","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.109.853689","article-title":"Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial","volume":"120","author":"Packer","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.09.017_bb0075","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1016\/j.jacc.2014.02.602","article-title":"Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)","volume":"63","author":"Fishbein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.017_bb0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ahj.2007.09.010","article-title":"Amiodarone use after acute myocardial infarction complicated by heart failure and\/or left ventricular dysfunction may be associated with excess mortality","volume":"155","author":"Thomas","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2019.09.017_bb0085","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jacc.2011.07.036","article-title":"Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses","volume":"58","author":"Saksena","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.017_bb0090","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.hrthm.2012.04.031","article-title":"Pharmacotherapy in Medicare beneficiaries with atrial fibrillation","volume":"9","author":"Piccini","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2019.09.017_bb0095","doi-asserted-by":"crossref","unstructured":"Piccini JP, Fraulo ES, Ansell JE et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011;162:606-612 e1.","DOI":"10.1016\/j.ahj.2011.07.001"},{"key":"10.1016\/j.ahj.2019.09.017_bb0100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/europace\/eum191","article-title":"Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association","volume":"9","author":"Kirchhof","year":"2007","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2019.09.017_bb0105","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/europace\/eut204","article-title":"Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF","volume":"15","author":"Chiang","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2019.09.017_bb0110","doi-asserted-by":"crossref","first-page":"622","DOI":"10.5603\/CJ.a2015.0055","article-title":"Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease","volume":"22","author":"Qin","year":"2015","journal-title":"Cardiol J"},{"key":"10.1016\/j.ahj.2019.09.017_bb0115","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/CIRCULATIONAHA.109.875252","volume":"120","author":"Connolly","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.09.017_bb0120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.hrthm.2014.03.006","article-title":"Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial","volume":"11","author":"Steinberg","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2019.09.017_bb0125","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2014.07.967","article-title":"Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation","volume":"64","author":"Flaker","year":"2014","journal-title":"insights from the ARISTOTLE trial. J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.017_bb0130","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/eurheartj\/ehv201","article-title":"Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial","volume":"36","author":"Steffel","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.09.017_bb0135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.cardfail.2007.02.009","article-title":"The safety of amiodarone in patients with heart failure","volume":"13","author":"Torp-Pedersen","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2019.09.017_bb0140","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","article-title":"heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial","volume":"103","author":"Lechat","year":"2001","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319302753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319302753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:50Z","timestamp":1762077470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319302753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"alternative-id":["S0002870319302753"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.09.017","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}